Colistin의 용량 적절성 평가 및 제언 = The Evaluation of Dose Adjustment of Colistin and Proposal

다국어 초록 (Multilingual Abstract)

Colistin was used for only external application due to its nephrotoxicity and neurotoxicity when it was administered for IV route is increased because Multidrug resistant (MDR) microorganisms is increased in 2000s. The dosage for Colistin has to be adjusted according to Serum Creatinine (Scr) level, which indicates renal function failure. However, Scr has many other factors that influence its level to limit renal function failure. We evaluated the dose adjustment according to Scr and Creatinine clearance (CLcr), and compared the outcomes and adverse drug reactions, in order to consider new renal dosing.
This study retrospectively reviewed the medical records of adult patients of more than 19 years old admitted to SNUH from July 2008 to July 2010, who had been treated with Colistin for more than continuous 4 days, and excluded patients with renal replacement therapy (HD/CRRT).
A total of 74 patients, out of 159 Scr cases were evaluated. Appropriate rate of Scr criteria was 45.9%, and appropriate rate of CLcr criteria was 35.8%. In addition, there were lower nephrotoxicity expression rate when the right dose were used, according to CLcr criteria. For the normal renal function group Scr≤1.3mg/dL, CLcr≥90mL/min, it is considered that dose adjustment according to CLcr criteria is more reasonable than that of Scr criteria.

참고문헌 (Reference)

1 Falagas M.E, "the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections" 40 : 1333-1341, 2005

2 Nation R.L, "optimizing Use of Colistin and Polymyxin B in the Critically Ill" 28 (28): 646-655, 2007

3 Sabuda D.M, "Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa" 19 (19): 413-418, 2008

4 Linden P.K, "Use of parenteral colistin for the treatment of serious infection due to antimicrovial-resistant Pseudomonas aeruginosa" 37 (37): 154-160, 2003

5 Garnacho-Montero J, "Treatment of multidrug-resistant Acinetobacter baumannii ventilatorassociated pneumonia (VAP) with intravenous colistin: a comparison with imipenem- susceptible VAP" 36 (36): 1111-1118, 2003

6 Beringer P, "The clinical use of colistin in patients with cystic fibrosis" 7 : 434-440, 2001

7 Sarkar S, "Resurgence of colistin use" 64 (64): 2462-2466, 2007

8 David M.D, "Potential for underdosing and emergence of resistance in Acinetovacter baumannii during treatment with colistin" 61 (61): 962-964, 2008

9 Mendes C.A, "Polymyxinsreview with emphasis on nephrotoxicity" 55 (55): 752-759, 2009

10 Coly-Mycin M., "Parenteral [package insert]"

11 Falagas M.E, "Nephrotoxicity of intravenous colistin: a prospective evaluation" 26 (26): 504-507, 2005

12 Falagas M.E, "Nephrotoxicity of intravenous colistin: a prospective evaluation" 26 (26): 504-507, 2005

13 Shemesh O, "Limitations of creatinine as a filtration marker in glomerulopathic patients" 28 : 830-838, 1985

14 Hachem R.Y, "Colistin is effective in treatment of infections caused by multidrug- resistant Pseudomonas aeruginosa in cancer patients" 51 (51): 1905-1911, 2007

15 Deryke C.A, "Colistin dosing and Nephrotoxicity in a large community teaching hospital" 54 (54): 4503-4505, 2010